Silverback Therapeutics (SBTX) Competitors $11.18 -0.14 (-1.24%) (As of 12/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends SBTX vs. QURE, ETNB, PLRX, CDMO, IMNM, KURA, KROS, TYRA, ERAS, and EOLSShould you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include uniQure (QURE), 89bio (ETNB), Pliant Therapeutics (PLRX), Avid Bioservices (CDMO), Immunome (IMNM), Kura Oncology (KURA), Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Erasca (ERAS), and Evolus (EOLS). These companies are all part of the "pharmaceutical preparations" industry. Silverback Therapeutics vs. uniQure 89bio Pliant Therapeutics Avid Bioservices Immunome Kura Oncology Keros Therapeutics Tyra Biosciences Erasca Evolus uniQure (NASDAQ:QURE) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, community ranking, valuation, earnings, dividends, analyst recommendations and risk. Which has more risk and volatility, QURE or SBTX? uniQure has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Do insiders and institutionals have more ownership in QURE or SBTX? 78.8% of uniQure shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 4.7% of uniQure shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is QURE or SBTX more profitable? Silverback Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -837.80%. Silverback Therapeutics' return on equity of -29.62% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets uniQure-837.80% -188.82% -32.17% Silverback Therapeutics N/A -29.62%-28.20% Does the MarketBeat Community favor QURE or SBTX? uniQure received 635 more outperform votes than Silverback Therapeutics when rated by MarketBeat users. Likewise, 70.67% of users gave uniQure an outperform vote while only 56.25% of users gave Silverback Therapeutics an outperform vote. CompanyUnderperformOutperformuniQureOutperform Votes65370.67% Underperform Votes27129.33% Silverback TherapeuticsOutperform Votes1856.25% Underperform Votes1443.75% Which has stronger earnings & valuation, QURE or SBTX? Silverback Therapeutics has lower revenue, but higher earnings than uniQure. Silverback Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiouniQure$28.59M28.95-$308.48M-$4.96-3.42Silverback TherapeuticsN/AN/A-$89.48M-$2.42-4.62 Does the media prefer QURE or SBTX? In the previous week, uniQure had 8 more articles in the media than Silverback Therapeutics. MarketBeat recorded 9 mentions for uniQure and 1 mentions for Silverback Therapeutics. uniQure's average media sentiment score of 0.19 beat Silverback Therapeutics' score of 0.00 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Silverback Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate QURE or SBTX? uniQure presently has a consensus target price of $33.88, indicating a potential upside of 99.50%. Given uniQure's stronger consensus rating and higher possible upside, research analysts clearly believe uniQure is more favorable than Silverback Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score uniQure 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryuniQure beats Silverback Therapeutics on 12 of the 18 factors compared between the two stocks. Ad WealthPress70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << Get Silverback Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBTX vs. The Competition Export to ExcelMetricSilverback TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$403.13M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-4.6210.5990.0517.18Price / SalesN/A195.801,117.14116.99Price / CashN/A57.1643.0437.86Price / Book1.515.094.784.78Net Income-$89.48M$151.83M$120.31M$225.60M7 Day Performance-6.05%-2.13%-1.92%-1.23%1 Month Performance-17.49%-3.10%11.51%3.36%1 Year Performance121.83%11.54%30.61%16.60% Silverback Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBTXSilverback TherapeuticsN/A$11.18-1.2%N/A+116.0%$403.13MN/A-4.6283News CoverageHigh Trading VolumeQUREuniQure3.5116 of 5 stars$17.31+12.4%$32.13+85.6%+172.3%$843.74M$28.59M-3.36500Analyst ForecastETNB89bio1.78 of 5 stars$7.87+2.3%$30.33+285.4%-22.4%$835.21MN/A-2.6440News CoveragePositive NewsPLRXPliant Therapeutics3.3626 of 5 stars$13.66+2.7%$40.50+196.5%-19.0%$831.21M$1.58M0.0090CDMOAvid Bioservices2.4254 of 5 stars$12.35+0.1%$12.25-0.8%+98.4%$789.94M$150.45M-5.17371IMNMImmunome2.561 of 5 stars$12.44-1.1%$28.83+131.8%+33.0%$776.47M$10.13M-1.5540Positive NewsKURAKura Oncology4.48 of 5 stars$9.89+2.7%$29.38+197.0%-27.0%$769.05MN/A-4.08142KROSKeros Therapeutics3.2934 of 5 stars$18.92+0.5%$81.33+329.9%-49.6%$766.39M$651,000.00-3.61100High Trading VolumeTYRATyra Biosciences2.0666 of 5 stars$14.99+0.3%$31.00+106.8%+2.0%$758.49MN/A-9.2820ERASErasca2.0792 of 5 stars$2.60+1.6%$5.90+126.9%+35.8%$735.09MN/A-3.08126News CoveragePositive NewsGap UpEOLSEvolus3.8237 of 5 stars$11.53+0.2%$23.00+99.5%+12.5%$730.08M$202.09M-12.73170 Related Companies and Tools Related Companies QURE Alternatives ETNB Alternatives PLRX Alternatives CDMO Alternatives IMNM Alternatives KURA Alternatives KROS Alternatives TYRA Alternatives ERAS Alternatives EOLS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SBTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silverback Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SBTX Stock Alerts